Anti-SARS-CoV-2 monoclonal antibodies for the treatment of active COVID-19 in multiple sclerosis: An observational study

Mult Scler. 2023 Mar;29(3):481-482. doi: 10.1177/13524585221103787. Epub 2022 Jun 28.

Authors

Federica Magnè¹, Maria Cellerino², Elisa Balletto¹, Kenda Aluan², Matilde Inglese^{2

3}, Malgorzata Mikulska^{1

2

3

4}, Matteo Bassetti^{1

4}

Affiliations

¹ Infectious Disease Clinic, Policlinico San Martino IRCCS, Genoa, Italy.
² Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Genoa, Italy.
³ Department of Neurology, Ospedale Policlinico San Martino IRCCS, Genoa, Italy.
⁴ Department of Health Science (DISSAL), Infectious Diseases Unit, University of Genoa, Italy.

No abstract available

Publication types

Observational Study
Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antibodies, Monoclonal
Antibodies, Viral
COVID-19*
Humans
Multiple Sclerosis*

Substances

Antibodies, Monoclonal
Antibodies, Viral